These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 37838081)
1. Transdermal Rotigotine at End-of-Life for Parkinson's Disease: Association With Measures of Distress. Hewer C; Richfield E; Halton C; Alty J J Pain Symptom Manage; 2024 Feb; 67(2):e121-e128. PubMed ID: 37838081 [TBL] [Abstract][Full Text] [Related]
2. Idiopathic Parkinson's Disease at the End of Life: A Retrospective Evaluation of Symptom Prevalence, Pharmacological Symptom Management and Transdermal Rotigotine Dosing. Hindmarsh J; Hindmarsh S; Lee M Clin Drug Investig; 2021 Aug; 41(8):675-683. PubMed ID: 34213758 [TBL] [Abstract][Full Text] [Related]
3. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease. Sanford M; Scott LJ CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211 [TBL] [Abstract][Full Text] [Related]
4. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study. Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231 [TBL] [Abstract][Full Text] [Related]
5. Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease. Lau YH; Leta V; Rukavina K; Parry M; Ann Natividad J; Metta V; Chung-Faye G; Chaudhuri KR J Neural Transm (Vienna); 2022 Jul; 129(7):889-894. PubMed ID: 35503480 [TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease: symptoms and medications at the end of life. Wilson EA; King-Oakley E; Richfield EW BMJ Support Palliat Care; 2024 Jan; 13(e3):e912-e915. PubMed ID: 37463763 [TBL] [Abstract][Full Text] [Related]
7. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease. Hirano M; Isono C; Fukuda K; Ueno S; Nakamura Y; Kusunoki S J Neurol Sci; 2019 Sep; 404():5-10. PubMed ID: 31323520 [TBL] [Abstract][Full Text] [Related]
8. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100 [TBL] [Abstract][Full Text] [Related]
9. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K; Lyons KE Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease. Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880 [TBL] [Abstract][Full Text] [Related]